The FTSE 100 is trading within sight of its all-time peak, with the index at 10,713 versus a record of 10,935 - a gap of roughly 2%. That proximity to record territory comes alongside a stronger-than-expected UK retail reading: June retail sales rose 1.0% month-on-month versus a -0.3% consensus, and annual retail growth printed at 4.2% compared with a 2.3% forecast. Over the past 12 months the index has gained roughly 17.2%, but beneath the headline performance several heavyweight constituents remain priced materially below the fair values implied by quantitative models.
Market context
Year-to-date the FTSE 100 has returned about 7.86% and is being supported by a combination of factors including a firmer pound (GBP/USD: 1.3325 at the time of reporting), resilient consumer spending and an investor shift toward large-cap global earners. A structural point for the index is that much of FTSE 100 revenue comes from outside the UK - dollars, euros and emerging market currencies make up a large share of sales - so movements in sterling act as an earnings translation factor. A stronger pound tends to reduce sterling-reported revenue, but the underlying demand in overseas markets remains the primary driver for many constituents. The market also shrugged off new US tariffs of 10-12.5% implemented on a range of trading partners.
Deep-value names within the large-cap universe
Although the index-level performance looks healthy, quantitative screens identify six blue-chip stocks with double-digit fair value upside. The following sections unpack each name using the same metrics: forward price-to-earnings, free cash flow yield, dividend yield, recent revenue trends and the gap between current price and model fair value.
GSK - Largest implied mispricing
GSK registers the widest fair-value gap in the FTSE 100 large-cap screen, with a model suggesting a +52.4% upside from current levels. The shares trade at GBX 1,927 with a forward P/E of 10.4x and an 8.4% free cash flow yield. Revenue has moved from 30.3 billion to 31.4 billion to 32.7 billion across the reported periods, representing 4.0% last-twelve-month growth. Gross margin stands at 72.9%, a level noted as comparable to large technology companies. Risks highlighted in the model centre on ongoing litigation over zantac and project execution in the pipeline, but the valuation gap and a 3.5% dividend yield are cited as providing a significant margin of safety.
LSEG - Data and analytics toll-road
London Stock Exchange Group (LSEG) is characterized here not primarily as an exchange operator but as a financial data and analytics business with a reported gross margin of 88.1%. Revenue has expanded from 8.4 billion to 8.9 billion to 9.4 billion. The forward P/E has compressed to 17.8x from a 33.4x trailing P/E, which the analysis interprets as a signal of an approaching earnings inflection. The model gives LSEG a +30.2% fair value upside, while sell-side analyst targets are even more bullish at +38.9% - a rare alignment between quantitative valuation and consensus estimates. Year-to-date the share price is effectively flat, showing limited market recognition so far.
Diageo - Contrarian recovery case
Diageo presents a contrarian recovery scenario. Revenue has moved from 16.2 billion to 16.0 billion to 14.75 billion, translating into a -2.0% last-twelve-month change - an outcome attributed to post-pandemic normalisation and weakness in Latin America. At GBX 1,555 the stock trades on a 12.8x forward P/E, with a 5.5% free cash flow yield and a 4.1% dividend yield. The valuation model points to a +27.8% upside while analysts see +21.4% to their targets. The analysis notes the long-lived nature of the brand portfolio as a structural support for recovery when consumer cycles turn.
BP - Value and cash generation in energy
BP stands out for a combination of low forward P/E and high cash returns: shares at GBX 549 imply an 8.1x forward P/E, a 10.0% free cash flow yield and a 4.8% dividend yield. Brent crude trades at $97.92 at the time of reporting, a price that supports comfortable cash generation for integrated oil companies. Reported revenue has fallen from 163.4 billion to 139.2 billion as energy prices moderated, but last-twelve-month revenue shows a +4.1% increase indicating stabilisation. The model fair value implies an +18.8% upside to GBX 654. The risk profile includes volatility in oil prices and the long-term energy transition narrative, while the immediate cash yield is presented as a compelling income characteristic.
RELX - Quiet compounder with AI tailwinds
RELX is described as a consistent compounder: an analytics and information services company with a 66.4% gross margin and stable revenue growth at around +2.0% into 9.6 billion. After a -15.8% year-to-date correction the forward P/E is 17.2x, and the model suggests a +17.1% fair value upside while analysts see +24.0% to target. A 6.5% free cash flow yield is identified as providing a valuation floor. The narrative highlights potential upside from AI integration across legal and scientific publishing platforms.
AstraZeneca - Growth-at-reasonable-price in pharma
AstraZeneca is framed as the growth leader among the names covered, with revenue progressing from 35.9 billion to 43.2 billion to 43.6 billion and last-twelve-month growth of +9.9%. Reported gross margin is 81.5%, and the stock trades on a 16.5x forward P/E. Year-to-date performance is -7.7%, the weakest in the set, yet analyst targets imply +28.7% upside to their price objectives. The model fair value for AstraZeneca sits at GBX 14,020 versus a market price of GBX 12,739 at the time of reporting.
Macro tailwinds and headwinds
On the positive side, the stronger retail sales print and the FTSE 100s international revenue mix are cited as supporting the index even when domestic conditions are mixed. The analysis also notes that expectations of future rate cuts could re-rate dividend-oriented stocks and that sterling strength may attract foreign capital. On the downside, new US tariffs of 10-12.5% are flagged as a potential headwind for UK exports, geopolitical tensions such as US-Iran friction could keep oil prices volatile, and the indexs closeness to record highs - just 2% away - may limit the upside from a broad market rally.
Takeaway
While index-level performance signals robustness, the disconnect between headline momentum and individual-stock valuations highlights several opportunities for investors focused on yield, cash flow and long-term structural growth. The six names identified - GSK, LSEG, Diageo, BP, RELX and AstraZeneca - offer varying combinations of free cash flow, dividend income and modelled upside, but each carries company-specific risks that investors should weigh alongside macro developments.